Extended use of inclisiran safe and efficacious among refractory dyslipidemia in patients with increased CV risk
A recent study sheds light on the safety profile of inclisiran, an innovative agent designed to reduce low-density lipoprotein cholesterol (LDL-C). The research aimed to provide comprehensive evidence on the long-term safety of inclisiran, a small interfering RNA agent with promising implications for managing dyslipidemia. This study was published in the Journal Of The American College Of Cardiology by Scott Wright and colleagues.
The post hoc analysis encompassed patients treated with 300 mg inclisiran sodium or placebo across completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Key findings from the study:
Patient Cohort: The analysis involved 3,576 patients receiving inclisiran for up to 6 years and 1,968 patients on placebo for up to 1.5 years, accounting for 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were similar across groups, ensuring a balanced comparison.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.